Clinical trials: Oncologic Disease
Chemotherapy-induced Peripheral Neuropathy
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who…
- Trial name
- NCT05488873
- Testing
- WST-057 Active
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- WinSanTor, Inc
Triple Negative Breast Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in…
- Trial name
- NCT02032277
- Testing
- Cyclophosphamide, Doxorubicin, Paclitaxel
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 634 people
- Sponsor
- AbbVie
Colorectal Cancer, Colorectal Cancer (CRC)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal…
- Conditions
- Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC
- Trial name
- NCT07321106
- Testing
- CBI-1214
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cartography Biosciences
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Oncology, Interventional Radiology
Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
This clinical feasibility evaluation is intended to further characterize and quantify the potential benefits of the FDA-cleared XR90 Augmented Reality (AR )imaging and guidance platform utilization in percutaneous soft tissue…
- Conditions
- Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma
- Trial name
- NCT07046832
- Testing
- Augmented Reality Guided Biopsy, Ultrasound Guided Biopsy
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- MediView XR, Inc.
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT05257590
- Testing
- Nivolumab Injection [Opdivo], CVM-1118
- Where
- 5 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- TaiRx, Inc.
Medical Oncology
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
To evaluate the effect of itraconazole or rifampin on the absorption, distribution, metabolism and elimination of COPANLISIB (BAY80-6946).
- Trial name
- NCT02253420
- Testing
- Copanlisib (BAY80-6946), Itraconazole, Rifampin
- Where
- 5 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Hepatoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT04567615
- Testing
- Nivolumab, Relatlimab
- Where
- 65 sites in Argentina, Brazil and 15 more
- Volunteers
- 266 people
- Sponsor
- Bristol-Myers Squibb
Peripheral T-cell Lymphoma
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.
- Trial name
- COMPLETE (NCT01110733)
- Where
- 68 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Acrotech Biopharma Inc.
Cancer
Prospective Study to Assess a Diagnostic Aid for Cancer
The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.
- Trial name
- PROCARES (NCT07046260)
- Testing
- Blood sample collection
- Where
- 42 sites in United States
- Volunteers
- 2,450 people
- Sponsor
- Harbinger Health
Solid Tumors
AS703569 Phase I in Patients With Solid Tumours
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.
- Trial name
- NCT00391521
- Testing
- AS703569
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- EMD Serono
Lung Cancer Non-small Cell Stage IV
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed…
- Trial name
- NCT03866980
- Testing
- AK105, carboplatin, pemetrexed
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Akeso
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Multiple Myeloma, Patient Reported Outcome (PRO)
Digital Support for Multiple Myeloma Quality of Life
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.
- Conditions
- Multiple Myeloma, Patient Reported Outcome (PRO), Supportive Care in Cancer, Quality of Life
- Trial name
- DigiMyQoL (NCT07642362)
- Testing
- Digital support
- Where
- Greece
- Volunteers
- 108 people
- Sponsor
- CareAcross
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing…
- Trial name
- NCT06149910
- Testing
- Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- All4Cure
Advanced Malignancy, Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT01723020
- Testing
- AMG 232
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Kartos Therapeutics, Inc.
Acute Myeloid Leukemia
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT03671564
- Testing
- Milademetan
- Where
- 8 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals